CollPlant Biotechnologies (CLGN) Cash from Discontinued Operations (2020 - 2021)

CollPlant Biotechnologies (CLGN) posted Cash from Discontinued Operations of 2817000.0 for Q3 2021, up 13.59% on a QoQ basis from 3260000.0 in Q2 2021, and down 139.14% year-over-year from 7197000.0 in Q3 2020.

CollPlant Biotechnologies (CLGN) Cash from Discontinued Operations (2020 - 2021) Analysis & Trends

CollPlant Biotechnologies' Cash from Discontinued Operations history runs 2 years deep, the most recent figure standing at 2817000.0 for Q3 2021.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Discontinued Operations (Qtr)
1 Oculis Holding AG 66,621.14 Bn 66,620.85 Bn - -
2 Nanobiotix 1,915.18 Bn 1,915.11 Bn - -
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn - -
4 BeOne Medicines 471.27 Bn 466.48 Bn 1.35 Bn -
5 Vertex Pharmaceuticals 121.81 Bn 114.57 Bn 2.59 Bn -
6 Regeneron Pharmaceuticals 69.58 Bn 60.82 Bn 3.31 Bn -
7 Belite Bio 62.72 Bn 62.72 Bn - -
8 Argenx Se 55.51 Bn 50.33 Bn 1.41 Bn -
9 Revolution Medicines 37.35 Bn 37.35 Bn - -
10 CollPlant Biotechnologies 4.63 Mn 4.63 Mn -243,000.00 -

Historic Data

Download Data
DateValue
Sep 30, 2021 -2.82 Mn
Sep 30, 2021 -2.82 Mn
Jun 30, 2021 -3.26 Mn
Jun 30, 2021 -3.26 Mn
Mar 31, 2021 11.00 Mn
Mar 31, 2021 11.00 Mn
Sep 30, 2020 7.20 Mn
Sep 30, 2020 7.20 Mn
Jun 30, 2020 -1.76 Mn
Jun 30, 2020 -1.76 Mn
Mar 31, 2020 -2.59 Mn
Mar 31, 2020 -2.59 Mn